Mohammad Hashemi's Contact Details

Mohammad Hashemi's Company Details

Starpharma

Abbotsford, VIC, AU • 50 - 99 Employees
BioTech/Drugs

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP® drug delivery and VivaGel®. Starpharma is developing VIRALEZE™, an antiviral nasal spray for COVID-19 which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ also has potential use in future pandemics and is afforded expedited development because it is repurposing an already-marketed, broad-spectrum antiviral dendrimer, SPL7013. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is approved in >40 countries and available in for sale in the UK, Europe, South East Asia, Australia and New Zealand. As a leading company in dendrimer based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, which is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include programs with AstraZeneca and other world leading pharmaceutical companies, which have the potential to generate significant future milestones and royalties.